For instance, in accordance with the newly suggested guidelines [51] and according to our data from this study, patients carrying the HLA-A*24:02 genotype and experiencing BCR after local therapy may start ADT after metastatic disease diagnosis, thus avoiding for a long time the significant side effects of anti-androgens, and consequently enjoying an improved quality of life for longer periods. This evidence concerns the gene HLA-A and metastatic neoplasm.